FDA-cleared profile

AIRAscore

AIRAmed GmbH · MRI · FDA-cleared (510(k))

Authorized purpose: AIRAscore automatically labels, visualizes and quantifies segmentable brain structures from MR images, replacing manual volume measurement and providing reference-adjusted reports and annotated images for expert physician evaluation.

Clinical role
Segmentation and volumetric measurement
Images and patients
MRI · Brain
Key limitation
Keep in mind: Incoming MRI must meet technical requirements. Expert physicians evaluate reports and control images. Networks remain static during a software version. The described input is single-time-point T1 with optional FLAIR, not the predicate's CT or longitudinal input scope.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: AIRAscore automatically labels, visualizes and quantifies segmentable brain structures from MR images, replacing manual volume measurement and providing reference-adjusted reports and annotated images for expert physician evaluation.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: DICOM T1-weighted and optional FLAIR MR images from a single time point, checked against technical requirements before segmentation.
  • Who uses it?Intended users: Licensed physicians with expert knowledge in neuroanatomy and MR imaging of the head
  • What does the software produce?Output: Encapsulated PDF DICOM reports and Secondary Capture annotated images; structure reports include raw/intracranial-volume-relative values and reference percentiles. AIRAscore MS additionally reports white-matter lesion number, volume and juxtacortical/periventricular/infratentorial categories.
  • What is its most important limitation?Key limitation: Incoming MRI must meet technical requirements. Expert physicians evaluate reports and control images. Networks remain static during a software version. The described input is single-time-point T1 with optional FLAIR, not the predicate's CT or longitudinal input scope.

Clinical takeaway. Clinical role: AIRAscore automatically labels, visualizes and quantifies segmentable brain structures from MR images, replacing manual volume measurement and providing reference-adjusted reports and annotated images for expert physician evaluation.

Evidence takeaway. Evidence from the reviewed source record: Exact-submission technical validation is described without enough numerical detail for comparative performance. Stored publications remain unresolved version leads.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
AIRAscore automatically labels, visualizes and quantifies segmentable brain structures from MR images, replacing manual volume measurement and providing reference-adjusted reports and annotated images for expert physician evaluation.
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Segmentation and volumetric measurement
  • Exact FDA submission
  • Checked 2026-09-05
Required input
DICOM T1-weighted and optional FLAIR MR images from a single time point, checked against technical requirements before segmentation.
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Encapsulated PDF DICOM reports and Secondary Capture annotated images; structure reports include raw/intracranial-volume-relative values and reference percentiles. AIRAscore MS additionally reports white-matter lesion number, volume and juxtacortical/periventricular/infratentorial categories.
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Professional healthcare setting, including diagnostic workstation or physician's office
  • Exact FDA submission
  • Checked 2026-09-05
Intended users
Licensed physicians with expert knowledge in neuroanatomy and MR imaging of the head
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Incoming MRI must meet technical requirements. Expert physicians evaluate reports and control images. Networks remain static during a software version. The described input is single-time-point T1 with optional FLAIR, not the predicate's CT or longitudinal input scope.
  • Exact FDA submission
  • Checked 2026-09-05

The baseline's broad scanner-manufacturer label does not establish compatibility of every scanner/protocol. Current v3.1.0 contraindications are retained separately at family scope.

Evidence summary
Exact-submission technical validation is described without enough numerical detail for comparative performance. Stored publications remain unresolved version leads.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Exact-submission technical validation is described without enough numerical detail for comparative performance. Stored publications remain unresolved version leads.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

Disease-detection sensitivity with tested-version and population context was not established from this volumetry summary.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No numerical disease-detection specificity for K223180 was established.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K223180 AIRAscore accuracy, reproducibility and software validation

  • DesignManufacturer accuracy comparison to manually labeled ground truth, test-retest reproducibility and software validation
  • PopulationBrain MR images across target population and scanner manufacturers; sample details not reported in reviewed summary
  • Scopeexact submission
  • Tested versionAIRAscore configuration described in K223180
  • IndependenceSponsor or vendor study

K223180

No numerical performance estimate or independent clinical outcome is inferred.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM T1-weighted and optional FLAIR MR images from a single time point, checked against technical requirements before segmentation.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · FDA 510(k) K223180: AIRAscore

  2. Routing

    Source context, not route validation: A DICOM storage SCU sends generated reports to a defined storage SCP, usually the referring physician's PACS; annotated DICOM images support expert inspection.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · FDA 510(k) K223180: AIRAscore

  3. AI processing

    Source context, not route validation: Software as a service running on AIRAmed internal servers, with dedicated accessory interfaces for sending and receiving DICOM data.

    Scope: Exact FDA submission. Preserves the source-backed cloud baseline. Current region, retention, availability and commercial configuration need confirmation.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 · FDA 510(k) K223180: AIRAscore

  4. Returned objects

    Source context, not route validation: Encapsulated PDF DICOM reports and Secondary Capture annotated images; structure reports include raw/intracranial-volume-relative values and reference percentiles. AIRAscore MS additionally reports white-matter lesion number, volume and juxtacortical/periventricular/infratentorial categories.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · FDA 510(k) K223180: AIRAscore

  5. Viewer/worklist/report

    Unresolved route: Encapsulated PDF DICOM reports and Secondary Capture annotated images; structure reports include raw/intracranial-volume-relative values and reference percentiles. AIRAscore MS additionally reports white-matter lesion number, volume and juxtacortical/periventricular/infratentorial categories.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · FDA 510(k) K223180: AIRAscore

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Software as a service running on AIRAmed internal servers, with dedicated accessory interfaces for sending and receiving DICOM data.
  • Exact FDA submission
  • Checked 2026-09-05

Preserves the source-backed cloud baseline. Current region, retention, availability and commercial configuration need confirmation.

Integration
A DICOM storage SCU sends generated reports to a defined storage SCP, usually the referring physician's PACS; annotated DICOM images support expert inspection.
  • Exact FDA submission
  • Checked 2026-09-05

Current family IFU and operating restrictions

The official v3.1.0-rev2 IFU describes optional DICOM SR reports (disabled by default), error reports to PACS and required physician quality review. It excludes patients under 18 and specified structural brain abnormalities, and cautions against contrast-enhanced input.

product family · checked 2026-09-05

European IFU exported April 16, 2026; no exact K223180 release linkage. These later-release functions and exclusions are not silently assigned to the 2023 clearance.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K223180
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-08-25
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-05Last searched
20Fields reviewed
11Source classes checked
2Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored titles/dates screened: scan-rescan software comparison and CE-certified tool in SPG4 are possible family evidence, but neither metadata record establishes the K223180 release. Live PMID 40813790 was blank; 36543827 returned a browser-check page. No publication or trial result promoted; full-text/version assessment remains unresolved. Stored trial array empty. The current discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, literature index, trial registry, stored candidate metadata, stored recall candidates, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission

    Reviewed FDA and vendor IFU material does not establish an exact price, unit, term, minimum commitment or included support.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "AIRAmed reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No result was a vendor or payer page naming this product with coding or payment; any results were general billing guidance. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-05 - Exact FDA submission

    A data-transfer description and current IFU are not a scoped current security attestation for the K223180 deployment.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-05 - Exact FDA submission

    Required physician expertise is established, but exact-release training curriculum and competency/support terms are not.

  • Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission

    Editorial acceptance questions concern segmentation quality, DICOM age/sex integrity, failed-input reports and update comparability; no monitoring service is verified.

7 sources - 3 history items

Source ledger

  1. FDA 510(k) K223180: AIRAscore

    U.S. Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinicalUse, modality, anatomy, implementationCapabilities, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. AIRAscore model card (K223180)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, integration, anatomy, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. AIRAscore v3.1.0 Instructions for Use, revision 2

    AIRAmed GmbH - Accessed 2026-09-05

    Scope: productFamily, implementationCapabilities, limitations

Research history

  1. K223180 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K261405

ANDI 2.2

Imeka Solutions, Inc.

Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Modality
MRI
Anatomy
Brain
Decision
2026-05-28
FDA-cleared K260032

Morph

BeauBrain Healthcare, Inc.

Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Modality
MRI
Anatomy
Brain
Decision
2026-05-13
FDA-cleared K253057

AI-Rad Companion Brain MR

Siemens Healthcare GmbH

Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.

Modality
MRI
Anatomy
Brain
Decision
2026-01-22
FDA-cleared K252298

ANDI 2.0

Imeka Solutions, Inc.

Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.

Modality
MRI
Anatomy
Brain
Decision
2025-10-22

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history